Dermatology

No long-term PRO difference: Mepitel Film vs standard care for breast radiation dermatitis

In a randomized trial of 376 breast cancer patients, Mepitel Film did not differ from standard care in long-term patient-reported ARD symptoms up to 24 months. Pruritus was worse at 6 months and pigmentation persisted at 6, 12, and 24 months compared with baseline. No long-term safety signals were identified with Mepitel Film, though physical sign confirmation was recommended. These findings suggest MF is safe but does not reduce chronic itch or pigmentation after RT. 1

Delphi consensus defines moderate psoriasis beyond PASI/BSA

Fifteen Italian experts reached consensus on 18 statements creating a multidimensional, operational definition of moderate psoriasis. The definition incorporates clinical severity, QoL thresholds (DLQI), symptoms, special-area involvement, and relapse patterns. Authors propose these criteria to harmonize access to systemic therapies and reduce treatment variability. This consensus may aid earlier treatment decisions but requires external validation in other healthcare settings. 2

Mapping review finds no proven dengue therapeutic and poor trial comparability

This systematic mapping review identified 121 dengue therapeutic trials, with 72 published and 49 registered but unpublished studies. Heterogeneous endpoints and methodologic concerns left no treatment with consistent evidence for clinical use. Nearly half of efficacy-evaluable published trials had high or critical risk of bias, precluding meta-analysis. Authors recommend large, harmonized, low-bias trials with standardised endpoints before practice recommendations. 3